• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Case study November 22, 2021

Accurately identifying and predicting synthetic lethal partnerships, to combat cancerous cells

AI-guided precision cancer therapy platform


CHALLENGE AND GOAL

Identifying new molecular targets for targeted therapeutics is a critical area of active investigation in oncology. As, cancerous and other mutated cells are often “undruggable,” researchers continuously working to developnew treatments. Popular techniques such as cell line-based screens, have helped to save countless lives, however researchers still require a way to simplify the way to better understand cancer initiation or progression. 

SOLUTION AND OUTCOME

Identifying new molecular targets for targeted therapeutics is a critical area of active investigation in oncology. As, cancerous and other mutated cells are often “undruggable,” researchers continuously working to developnew treatments. Popular techniques such as cell line-based screens, have helped to save countless lives, however researchers still require a way to simplify the way to better understand cancer initiation or progression. 


Although medical researchers have made significant strides in curing and even eliminating diseases over the past century, developing cancer treatments is still one of the most difficult challenges to be addressed. 

To help medical researchers treat cells that have “undruggable mutations” researchers at SRI Biosciences, who have decades of experience in the bioinformatics field, created the Synthetic Lethals platform. This AI based platform accomplishes the large-scale discovery of synthetic lethal partners by recognizing patterns in vast amounts of pan-cancer primary tumor genomic and transcriptomic data utilizing multiple different databases and offers the ability to incorporate additional datasets.  

The platform integrates a novel computational approach that leverages AI to drug target discovery with cutting-edge pre-clinical validation to accelerate the discovery of new oncology drugs.  

The Synthetic Lethals platform has predicted synthetic lethal partners for a broad spectrum of cancer mutations, including loss-of-function mutations and gain-of-function mutations in multiple cancer types. To date, the AI platform-predicted synthetic lethal partners have been validated in in vivo tumor models for key recurrent mutations in acute myeloid leukemia, breast cancer, kidney cancer and lung cancer.  

Synthetic Lethals technology has a variety of applications in precision cancer therapy:  

  • Identify new drug targets to accelerate discovery of treatments for previously untreatable cancers  
  • Enable re-purposing of existing drugs for cancer treatment  
  • Facilitate identification of synergistic drug combinations 
  • Identify biomarkers to allow for precise use of targeted drugs 

Partnering Opportunities 

SRI Biosciences partners with commercial companies through research collaborations that lead to option and license agreements for further commercialization. Contact biosciences@sri.com to explore how SRI’s SL guided precision cancer therapy platform can optimize your oncology drug discovery program.  

Share this

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International